Island Pharmaceuticals now has the green light to send its drug Galidesivir into the heart of the crisis, a step the company believes could unlock broader global approvals.
Island Pharmaceuticals, which is listed on the ASX, confirms Uganda’s regulators have authorised Galidesivir for “compassionate use”, reserved for patients with life‑threatening illnesses lacking options. That approval allows the company to export its still‑experimental treatment directly into Ugandan clinics dealing with the current Bundibugyo Ebola virus outbreak.
Compassionate use programmes let doctors administer unapproved medicines when standard therapies offer little hope. The company positions this deployment as a real‑world test of Galidesivir’s potential against Ebola in humans.
Health authorities describe the Bundibugyo Ebola outbreak as the third‑largest on record, underscoring the urgency behind Uganda’s decision. The US Centres for Disease Control and Prevention reports 1561 cases across the Democratic Republic of Congo and Uganda and at least 508 deaths.
Ebola’s fatality rate can climb to about 50%, so even incremental improvements in treatment could translate into many lives saved. Against that backdrop, regulators are more willing to open tightly controlled pathways for experimental antivirals.
Galidesivir has already produced strong results in animal studies, according to Island Pharmaceuticals, which now wants to see whether those findings translate into human benefit. Traditional human trials remain heavily restricted by US Food and Drug Administration regulations that tightly manage how and where the drug can be tested.
Using compassionate access in an active outbreak gives the company a rare, though challenging, opportunity to collect data in real patients. The outcome of this deployment is likely to influence whether Galidesivir moves closer to mainstream regulatory approval.
